Modality
Nanobody
MOA
Menini
Target
PD-1
Pathway
Apoptosis
Ewing Sarcoma
Development Pipeline
Preclinical
Feb 2019
→ Nov 2028
PreclinicalCurrent
NCT05478760
897 pts·Ewing Sarcoma
2024-03→2025-08·Terminated
NCT08371345
65 pts·Ewing Sarcoma
2019-02→2028-11·Active
962 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-018mo agoInterim· Ewing Sarcoma
2028-11-022.6y awayInterim· Ewing Sarcoma
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Active
Preclinical
Termina…
Catalysts
Interim
2025-08-01 · 8mo ago
Ewing Sarcoma
Interim
2028-11-02 · 2.6y away
Ewing Sarcoma
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05478760 | Preclinical | Ewing Sarcoma | Terminated | 897 | SeizFreq |
| NCT08371345 | Preclinical | Ewing Sarcoma | Active | 65 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Motanaritide | Intellia | Approved | PD-1 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 |